Zobrazeno 1 - 10
of 1 933
pro vyhledávání: ''
Publikováno v:
Breast Cancer Research and Treatment
Purpose Breast cancer survivors take vitamins and supplements to bolster their general health and to decrease the risk of cancer recurrence. Healthcare providers are frequently unaware of their patients non-prescription supplement use. The aim of thi
Autor:
Boya Zhang, Jianpeng Yu, Yuanjie Niu, Zhiqun Shang, Qi Li, Shimiao Zhu, Mingpeng Zhang, Yanjie Yang
Publikováno v:
Oncogene
Castration-resistant prostate cancer (CRPC) is a highly malignant type of advanced cancer resistant to androgen deprivation therapy. One of the important mechanisms for the development of CRPC is the persistent imbalanced regulation of AR and AR spli
Autor:
Akihito Tsuji, Dai Manaka, Masato Kataoka, Masashi Fujii, Masahiro Takeuchi, Takanori Watanabe, Masato Nakamura, Wataru Ichikawa, Hiroshi Matsuoka
Publikováno v:
Targeted Oncology. 16:753-760
Regorafenib and trifluridine/tipiracil are standard third-line chemotherapies for colorectal cancer patients, but their efficacy is limited. Anti-epidermal growth factor receptor antibody rechallenge has been reported to be promising for patients who
Publikováno v:
Clinical and Translational Oncology. 24:540-545
After the wide use of linezolid (LZD), numerous reports of uncontrolled studies have suggested that LZD is associated with high rates of thrombocytopenia. We conducted this matched case–control study to identify the risk factors for LZD-induced thr
Autor:
Stephanie Burnett, Amit Bahl, Bruno Morgan, Lucy Tregellas, Lisa Pickering, Alastair Thomson, Emma Hall, Tony Elliott, Rachel Slade, Balaji Venugopal, Steve Nicholson, Naveen S. Vasudev, Holly Tovey, Clare Cruickshank, Peter Kirkbride, Alison Hassall, Anita Mitra
Publikováno v:
British Journal of Cancer
Background We investigated the first-line activity of vinflunine in patients with penis cancer. Cisplatin-based combinations are commonly used, but survival is not prolonged; many patients are unfit for such treatment or experience toxicity that outw
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Raphael Teipel, Susanne Quick, Stephan Richter, Holger Knoth, Theresa Kretschmann, Frank Kroschinsky, Christoph Röllig, Ekaterina Balaian, Nael Alakel, Martin Bornhäuser, Sandra Heuschkel, Malte von Bonin, Simone von Bonin
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose High-dose methotrexate (HDMTX)-associated acute kidney injury with delayed MTX clearance has been linked to an excess in MTX-induced toxicities. Glucarpidase is a recombinant enzyme that rapidly hydrolyzes MTX into non-toxic metabolites. The
Autor:
Xiaoqin Jia, Jieping Chen, Mei Kuang, Yu Hou, Chengfang Zhou, Weiru Wu, Zhe Chen, Zhilong Liu, Yuanyuan Liu, Le Ma, Zhigang Li
Publikováno v:
Leukemia. 36:834-846
FZR1 has been implicated as a master regulator of the cell cycle and quiescence, but its roles and molecular mechanisms in the pathogenesis of severe aplastic anemia (SAA) are unclear. Here, we report that FZR1 is downregulated in SAA HSCs compared w
Publikováno v:
Cellular Oncology. 44:1151-1166
Hepatocellular carcinoma (HCC) has emerged as a leading cause of cancer-related deaths globally, in which hypoxia and activated hypoxia-inducible factors (HIFs) play important roles. The sibling rivalry between HIF-1α and HIF-2α in hypoxic tumor gr
Autor:
Charles S. Kuzma, Harry P. Erba, Mark R. Litzow, Steven Coutre, Scott E. Smith, Richard Stone, Amy S. Ruppert, Allison M Booth, Nancy L. Bartlett, Jeremy S. Abramson, John C. Byrd, Jennifer A. Woyach, Jennifer R. Brown, Richard F. Little, Richard A. Larson, Sumithra J. Mandrekar, Wei Ding, Sreenivasa Nattam, Carolyn Owen, Danielle M. Brander
Publikováno v:
Leukemia
Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles versus continuous ibrutinib, complicate adverse event (AE) compar